Jpmorgan Chase & CO Emergent Bio Solutions Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 434 shares of EBS stock, worth $4,123. This represents 0.0% of its overall portfolio holdings.
Number of Shares
434
Previous 643
32.5%
Holding current value
$4,123
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding EBS
# of Institutions
164Shares Held
34.7MCall Options Held
474KPut Options Held
939K-
Black Rock Inc. New York, NY3.84MShares$36.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.2MShares$30.4 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO2.14MShares$20.3 Million0.01% of portfolio
-
State Street Corp Boston, MA1.96MShares$18.7 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA1.54MShares$14.6 Million0.0% of portfolio
About Emergent BioSolutions Inc.
- Ticker EBS
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 49,861,500
- Market Cap $474M
- Description
- Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...